Empagliflozin reduces CV death in patients with type 2 diabetes at high CV risk

Описание к видео Empagliflozin reduces CV death in patients with type 2 diabetes at high CV risk

David H. Fitchett, MD and Cardiologist at St. Michael's Hospital at the University of Toronto discusses the effect of empagliflozin on mortality and causes of death in patients with type 2 diabetes at high cardiovascular risk at the American College of Cardiology 65th Annual Scientific Session & Expo (ACC.16).

MDLinx Conference Coverage - American College of Cardiology 65th Annual Scientific Session & Expo (ACC.16): http://www.mdlinx.com/cardiology/conf...

MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/

Follow MDLinx:
Facebook -   / mdlinx  
Twitter -   / mdlinx  
Google+ - https://plus.google.com/+Mdlinx/

Комментарии

Информация по комментариям в разработке

Похожие видео